Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Loures, Portugal, 19 October 2011 – Hovione today announced the launch of its Rapid Proof of Concept Study for the development of dry powder inhalation (DPI) products.
Building on Hovione's well established DPI development capability, the new service simplifies the development of formulations, producing a proof of concept formulation of a client's molecule in just a few weeks.
Hovione has simplified DPI product development, reduced complexity and reduced the time required for completion by mastering, in concert, particle engineering, formulation technology and inhaler design, the three disciplines vital to the development of a successful product. Unlike other CROs, Hovione has all of this expertise under one roof, eliminating the coordination issues clients often experience in having to use multiple CROs. The results of this are reduced coordination costs, shortened development timescales and a stream-lining of the development process.
Peter Villax, Hovione's Vice President of Pharma & Innovation commented “this new Rapid Proof of Concept service offers clients a low risk look at the feasibility of developing a DPI product and gives clients greater confidence about going into later stage development”. “Clients of the new service don't just get a report, they get their first DPI formulation” he added.
In a short period of time and for relatively little investment, a drug developer can acquire a DPI formulation, potentially adding significant value to an early stage out-licensing opportunity or helping a company move into a stronger position in funding negotiations with venture capitalists.
Hovione is an international company with over 50 years’ experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Contacts at Hovione
Phil Nelson, PhD
Business Development Manager
+351 219 847 619
+351 219 829 362